



SOLVENCY AND FINANCIAL CONDITION REPORT 2022



AETNA HEALTH INSURANCE COMPANY OF EUROPE DAC
Alexandra House, 3, Ballsbridge Park, Ballsbridge Dublin 4



Solvency and Financial Condition Report 2022
Aetna Health Insurance Company of Europe DAC

CONTENTS

EXECUTIVE SUMMARY.....	3
A. BUSINESS PERFORMANCE.....	6
A.1 Business	6
A.2 Underwriting Performance	9
A.3 Investment Performance	10
A.4 Performance of Other Activities	11
A.5 Any other information.....	12
B. SYSTEM OF GOVERNANCE.....	13
B.1 General Information on the System of Governance.....	13
B.2 Fit and proper requirements	15
B.3 Risk Management System.....	16
B.4 Internal Control System	19
B.5 Internal Audit Function	20
B.6 Actuarial Function.....	21
B.7 Outsourcing	21
B.8 Any other information.....	23
C. RISK PROFILE.....	24
C.1 Underwriting Risk	24
C.2 Market Risk.....	25
C.3 Credit Risk	26
C.4 Liquidity Risk	27
C.5 Operational Risk	28
C.6 Stress Testing and Sensitivities.....	28
C.7 Regulatory risk and capital management.....	31
C.8 Other Material Risks	31
C.9 Other material information	31
D. VALUATION FOR SOLVENCY PURPOSES	32
D.1 Assets.....	32

D.2	Technical Provisions	34
D.3	Other Liabilities.....	37
D.4	Alternative Valuation Methods.....	37
D.5	Other Material Information	37
E.	CAPITAL MANAGEMENT	38
E.1	Own Funds	38
E.2	SCR and MCR.....	41
E.3	Material Changes in the SCR and MCR over the Reporting Period.....	41
E.4	Use of duration-based equity sub-module in the calculation of the SCR	41
E.5	Differences between the Standard Formula and Internal Model used.....	41
E.6	Non-Compliance	42
	QRT Templates for the SFCR Public Disclosure	43
	Appendix 1 Balance Sheet	44
	Appendix 2 Premiums Claims Expenses.....	46
	Appendix 3 Premiums Claims Expenses by Country	47
	Appendix 4 Non Technical Provisions.....	48
	Appendix 5 Non Life Insurance Claims	49
	Appendix 6 Own Funds	50
	Appendix 7 Solvency capital requirement.....	51
	Appendix 8 Minimum Capital requirement.....	52



EXECUTIVE SUMMARY

The current harmonised European Union regulatory regime for insurance companies, known as Solvency II, came into force with effect from 1 January 2016. This report is the fourth Solvency and Financial Condition Report (“**SFCR**”) that Aetna Health Insurance Company of Europe DAC (“**AHICE**” or “**the Company**”) has been required to publish under the Solvency II regime having been authorised by the Central Bank of Ireland under the European Union (Insurance and Reinsurance Regulations 2015) to undertake non-life insurance from 1 January 2019.

This report covers the following in relation to the Company during the reporting period 1 January 2022 to 31 December 2022 (the “**Reporting Period**”): its Business and Performance, its System of Governance, its Risk Profile, its Valuation for Solvency Purposes and its Capital Management. The Company reports its financial results in Euro (“**EUR**” or “**€**”) and the figures in this report are stated are in Euro.

AHICE Business

The Company is an Irish authorised and regulated insurance company which forms part of the Aetna International division (“**Aetna International**” and “**AI**”) of the CVS Health Corporation Group of companies (“**CVS Group**”).

In March 2022 Aetna International executed an Asset Purchase Agreement (“**APA**”) with Allianz for the asset sale of its insurance and reinsurance business via an exclusive introduction process. The APA includes the business written by the Company.

Under terms agreed in the APA, Allianz is providing new business invitations to existing Aetna International customers in advance of their policy end date, at the point where they would have previously been offered renewal terms with Aetna International. Where customers choose to take out a new policy with Allianz, AI will support the migration of those customers to Allianz.

The APA became effective in May 2022 and Allianz started issuing renewal invitations to Aetna existing customers in July 2022. The AI customers will receive the invitations from Allianz on a phased basis as their existing Aetna policies expire and this process is expected to be completed by 31st October 2023.

As a consequence of implementing the APA with Allianz, at the close of business on 31st October 2022, the Company ceased writing business. On 21st November 2022, the AHICE Board formally approved for the Company to enter into run-off and approved a detailed run-off plan which was submitted to the Central Bank.

Business Performance

The earned revenue for the year was €17,312k (2021: €12,259k) and the underwriting result was €6,131k (2021: €4,915k). Net operating costs were €9,231k (2021: €2,412k), which included acquisition costs of €1,226 (2021: €1,067k) and costs associated with the APA €3,674k (2021: Nil).

The Solvency II technical provisions were €6,757k (2021: €5,142k), including allowance for run-off expenses of €2,256k (2021: Nil). Excluding the run-off expenses, the Technical provisions were in line with the reduced level of business for the commencement of the business migration under the APA and the cessation of writing business on 31st October 2022.

Capital Management

The Company currently uses the Solvency II Standard Formula to calculate its solvency capital requirement. The Company has a mono-line product with contracts renewable on an annual basis. The Company also reviews its capital requirements against capital models from rating agencies and its Board of Directors is satisfied that the Solvency II Standard Formula is, and remains, the most appropriate method for determining its solvency requirements.

The Company's Solvency Capital Requirement ("SCR") calculated under the Solvency II Standard Formula at 31st December 2022 is €3,355k (2021: €6,116k) and the Minimum Capital Requirement of €2,500k remains unchanged (2021: €2,500k). The Company has €13,636k of eligible Own Funds (2021: €17,033k) to meet the Solvency Capital Requirement of €3,355k, providing a solvency surplus of €10,381k (2021: €10,917k) and a solvency ratio of 419% (2021: 278%). The increase in the solvency ratio reflects the reduced SCR requirement, mainly arising from the reduced health risk margin as the business has decreased in the second half of the year due to the commencement of the APA migration and the cessation of writing all business on 31st October 2022.

Solvency Position as at 31 December	2022	2021
	€'000	€'000
Eligible Own Funds to meet SCR	13,636	17,033
Solvency Capital Requirement (SCR)	3,255	6,116
Surplus	10,381	10,917
Solvency Ratio	419%	278%
Minimum Capital Requirement (MCR)	2,500	2,500
Eligible Own funds as a percentage of MCR	545%	681%

The Board is satisfied with the capital management process in place to ensure the Company meets its regulatory capital requirements to the board approved risk appetite (minimum 150% solvency ratio).



Solvency and Financial Condition Report 2022
Aetna Health Insurance Company of Europe DAC

System of Governance

The Board of directors of the Company (“**Board**”) has overall responsibility for ensuring that the Company has an effective system of governance. It is responsible for overseeing the conduct of the Company’s business and supervising the executive team which is responsible for its day-to-day management. The Board manages its affairs in accordance with the constitution of the Company, its terms of reference and the legal & regulatory framework in which the Company operates. The Board is supported by two sub-committees, an Audit Committee and a Risk Committee, both of which were convened and operated in accordance with their respective terms of reference.

The Company operates a three lines of defence internal control system with the business acting as the first line of defence (owning/managing risks and implementing controls); compliance and risk management as the second line (monitor and challenge the first line controls); and internal audit as the third line of defence (providing independent assurance to the Board on the effectiveness of the Company’s governance, risk management, and internal controls).

Risk Management

The Company’s risk management system is fully integrated into the strategic planning and annual business plans approved by the Board. The Own Risk & Solvency Assessment process provides the Board with updates on the Company’s risk profile and assists it to capital plan over a three-year horizon.

A risk scorecard is used to report on risk tolerances and provide the baseline for risk scenario testing.

A. BUSINESS PERFORMANCE

A.1 Business

Company Details

Aetna Health Insurance Company of Europe DAC (hereinafter referred to as “**AHICE**” or the “**Company**”) is a private company limited by shares which is incorporated in Ireland with company number 448763. Its registered address and principal place of business is Alexandra House, 3 Ballsbridge Park, Ballsbridge, Dublin D04 C7H2.

Regulators

The Company is an Irish authorised insurance company providing international private medical insurance for individuals and groups. It is authorised by the Central Bank of Ireland (“CBI”) with firm reference number C47511.

The contact details for the CBI can be found on their website:

<https://www.centralbank.ie/>

External Auditors


The Company's external auditor is EY Chartered Accountants, Harcourt Centre, Harcourt Street Dublin 2 D02 YA40.

Legal Structure & Qualifying Holdings

The Company forms part of the Aetna International division of the Aetna Group which sits under CVS Health Corporation, a company incorporated in Delaware (USA).

A simplified group structure diagram is included on the next page which shows the holders of qualifying holdings in the Company.

**Legal Entity Organization
Chart As at 31 December 2022
(extract)**



Products

Prior to entering run-off, all IPMI plans sold by the Company were short-term in nature and renewable by invitation on an annual basis. There were two types of pricing structure:

Community rated

Community rated products include a pricing structure for a single population, with different price points depending on age and location. These were typically purchased by individuals and small employer sponsored groups.

Experience rated

Experience rated products offered to larger employer sponsored groups (100+ employees), where a target claims fund was set by reference to the historical claims experience. The claims fund for each experience rated group was reviewed on an annual basis.

The plan designs included a common architecture and structure for benefit tables, which facilitated the performance of claims analytics across the entire Aetna International book of business. The cost of medical treatments was assessed and compared across the multiple locations, with the Company approving annual premium increases to cover medical cost inflation for the Company's products and/or to correct the Company's claims exposure for experience rated groups. Premium adjustments are calculated and are effective from the date any changes are made to the number of employees or family members covered under the annual policies.

Business and significant events in the Reporting Period

In March 2022 Aetna International executed an Asset Purchase Agreement ("APA") with Allianz for the asset sale of its insurance and reinsurance business via an exclusive introduction process. The APA includes the business written by the Company.

Under terms agreed in the APA, Allianz is providing new business invitations to existing Aetna International customers in advance of their policy end date, at the point where they would have previously been offered renewal terms with Aetna International. Where customers choose to take out a new policy with Allianz, AI will support the migration of those customers to Allianz.

The APA became effective in May 2022 and Allianz started issuing renewal invitations to Aetna existing customers in July 2022. The AI customers will receive the invitations from Allianz on a phased basis as their existing Aetna policies expire and this process is expected to be completed by 31st October 2023.

As a consequence of implementing the APA with Allianz, at the close of business on 31st October 2022, the Company ceased writing business. On 21st November 2022, the AHICE Board formally approved for the Company to enter into run-off and approved a detailed run-off plan which was submitted to the Central Bank.

The Company is sufficiently capitalised to maintain a solvency ratio in line with its risk appetite (minimum solvency cover 150%) during the run-off period, including any additional costs associated with the wind down of the business.

A.2 Underwriting Performance

The Company had a single product, international private medical insurance. It was positioned to support the Aetna International strategy to provide international private medical insurance to employer sponsored groups and individuals in multiple locations.

The Company commenced a phased migration of business in August 2022, consistent with the terms agreed in the APA, and ceased to write any new or renewal business after 31st October 2022.

The following table summarises the underwriting result for the year ended 31 December 2022.

Underwriting result	2022	2021
	€'000	€'000
Net Written Premiums	14,205	17,430
Earned Revenue	17,312	12,259
Net Incurred Claims Costs	(11,181)	(7,344)
Underwriting Result	6,131	4,915

The Company does not report its results by business segment in the financial statements and shows the total underwriting result for the single product line in the profit and loss account. The notes to the financial statements include additional information on premiums, which is shown in the table below:

Gross Written Premiums	2022	2021
	€'000	€'000
EU	18,170	15,999
UK	279	71
Other Non-EU Countries	1,085	2,873
Total	19,534	18,943

A.3 Investment Performance

All assets are invested in a manner that ensures the security, quality, liquidity and profitability of the portfolio as a whole. The Company maintains assets to match its policyholder liabilities at all times. The Board has outsourced the management of its investments to the CVS Group Treasurer who manages its investments in accordance with the Board approved investment risk parameters and liquidity requirements. This places emphasis on low risk (minimum rating BBB) and highly liquid assets. The Board has approved a target 0%-100% mix for invested assets in government bonds and commercial paper or corporate bonds with minimum credit rating of BBB, and the weighting of the invested assets in commercial paper and corporate bonds is 100%.

The assets held by the Company in its investment portfolio as at 31 December 2022 are listed in the table below:

Financial Investments	2022	2021
	€'000	€'000
Cash on demand	18,422	17,820
Commercial paper	3,048	2,849
Total	21,470	14,188

The value of assets under management is affected by asset and currency performance. Investment income comprises interest, realised gains and losses on investment and unrealised gains and losses. Movements are recognised in the profit and loss account in the period in which they arise. Interest is accounted for on a time proportion basis using the effective interest method.

The table below provides an overview of the income and expense arising from the Company's investment assets:

Investment return – Commercial Paper	2022	2021
	€'000	€'000
Interest Income	55	3
Net (losses)/gains on realisation of investments	66	15
Investment return – Commercial Paper	121	18

The investment return reflects the conservative strategy adopted by the Board. The income on the invested assets increased due to rising interest rates.

The cash on deposit yields no investment return but allows for cash to be withdrawn on demand.

Other assets and liabilities held in currencies other than the reporting currency, Euro, are subject to foreign currency revaluation changes when valued in the reporting currency. The foreign currency unrealised gains/losses are included in the total investment.

The total financial income is shown in the table below:

Total Financial Income Return	2022	2021
	€'000	€'000
Commercial Paper	120	17
Cash	0	0
Other assets/liabilities – unrealised gains/(losses) on investments	1	1
Total Financial Income Return	121	18

A.4 Performance of Other Activities

The Company's only activities during the Reporting Period have been insurance and related activities.

Operating costs of the Company include acquisition costs and administration expenses directly incurred by the Company, including audit, other professional fees and banking charges.

The table below provides an overview of these costs for the Reporting Period.

Operating Costs	2022	2021
	€'000	€'000
Acquisition Costs	1,226	1,067
Administration costs - insurance business	8,005	1,346
Other administration income/charges	(1,685)	(119)
Total Costs	7,546	2,294

No dividends were paid during the Reporting Period which is consistent with the prior year.

A.5 Any other information

Events in the Ukraine

The Company does not have any direct exposure to events in the Ukraine, or business transactions in Russia and Belarus. The Company has determined that any other exposure from events arising in the Ukraine is not material to its business.

There is no other material information to report in relation to the Company's business and performance during the Reporting Period (save as otherwise covered elsewhere in this report).

Subsequent Event

On 1st January 2023 the Company entered into a quota share reinsurance arrangement with Aetna Life Insurance Company CT ("ALIC"), a related entity within the CVS Health Group. Under this arrangement the Company will transfer 100% of the economic risk for its insurance activity to ALIC. This includes any unearned components and established reserves for in-force business as of 1st January 2023 and their future economic developments. Reinsurance premium will be owed to ALIC on a funds withheld basis and ALIC will reimburse the Company for all paid claims. ALIC will pay the Company a ceding commission in compensation for the expenses the Company incurs from its managing general underwriting agencies who will continue the administration of the business activity.

The excess of loss reinsurance arrangement with Aetna Life & Casualty (Bermuda) Limited ("AL&C") was fully commuted on 31st December 2022, immediately prior to the commencement of the quota share reinsurance arrangement with ALIC.

B. SYSTEM OF GOVERNANCE

B.1 General Information on the System of Governance

- **The Board, its sub-committees and executive management**

The Board has overall responsibility for ensuring that it has an effective system of governance. It is responsible for overseeing the conduct of the Company's business and supervising the executive team which is responsible for its day-to-day management. The Board manages its affairs in accordance with the constitution of the Company, its terms of reference and the legal & regulatory framework in which the Company operates. The Board was comprised of five directors as at 31st December 2022: three non-executive directors and two executive directors, as well as the company secretary.

The Board has delegated certain of its responsibilities directly to the executive management team and its sub-committees. During the Reporting Period, there were two Board sub-committees with terms of reference which set out their roles and responsibilities:

- **Audit Committee**

The committee has responsibility for the oversight of the Company's financial reporting process, its audit process, its system of internal controls, compliance with laws & regulations. This committee is comprised of the full Board. The finance, compliance, and internal audit functions all provide quarterly updates on their activities to this committee.

- **Risk Committee**

This committee was responsible during the Reporting Period for the management of all aspects of the Company's risk exposure, including determining risk appetite and tolerances within an appropriate risk framework. This committee was comprised of the full Board.

- **Executive Management Team**

During the Reporting Period, the Company's executive management team was comprised of the Chief Executive Officer, the Chief Risk Officer, the Chief Finance Officer, the Underwriting Manager and Compliance Officer. They had overall management accountability for the day-to-day business of the Company and were responsible for reporting on such matters to the Board and its sub-committees.

EMEA Regional committees


The executive management team are supported by three regional committees:

- Executive Committee;
- Sales & Marketing Committee; and
- Legal, Audit, Risk & Compliance Committee.

which facilitate process management, awareness and appropriate governance amongst the key functions of the business.

The Company's executive management team remain directly responsible for implementing any group strategy at the Company level and decisions with respect to how the Company should conduct its Irish regulated business.

An overview of the key functions of the Company and its key function holders (including their respective Company reporting lines) was reviewed for entering run-off and is shown in the diagram on the next page.



The following changes occurred on the Board in the reporting period

- Mr Laurent De Veyrac resigned as CEO and Executive Director on 31st July 2022
- Mr David Gleeson was appointed as Executive Director on 29th July 2022
- Mr Brian O'Rourke, existing Executive Director, was appointed CEO of the Company on 1st August 2022

Remuneration policy and practices

The Company has a remuneration policy for all employees, which includes a mixture of fixed pay and bonus incentives.

The Human Resource function completes market research for employees to set bench-marked pay ranges for fixed pay. The market research also reviews additional market-based benefits which can be added to the basic compensation package.

The Company offers a defined contribution pension for employees and the contribution rates are set based on market research. The bonus incentives are linked to personal performance and the performance of the CVS Group. The performance of the Company is included in the total performance calculations for determining bonus funding approved by the CVS Group and there are no incentives linked specifically to the Company's performance.

The Chairman and Chief Executive Officer of the Company meet on an annual basis to review the remuneration policy to ensure it is appropriate for the Company.

Assessment of Corporate Governance Structure

The governance structure has been designed to ensure that management can provide the necessary oversight of the business and make decisions, whilst also supporting the responsibilities of the Board. The Board has clearly defined responsibilities and delegated authorities to its sub-committees.

The CVS Group sets the broad business strategy for the Company. The Board reviews the Company's strategy and annual business plan, which is prepared by the executive management team and is aligned with the broad strategic direction from the CVS Group.

The Board scrutinises the strategy and business to assess its risk and benefits and determine if its implementation is in accordance with:

- the Company's risk appetite.
- the Company's short term and long-term strategy.
- the Company's legal and regulatory responsibilities; and
- the fair treatment of the Company's policyholders.

The governance structure provides a mechanism for the Company to anticipate and respond to potential changes in the business environment or its risk profile in an appropriate amount of time. The risk management structure integrates risk assessment into the strategic and business planning cycles, which enables the Company to maintain a manageable risk profile.

B.2 Fit and proper requirements

The Company has a documented procedure for ensuring that all senior management functions ("**Pre-Approved Control Functions PCFs and Control Functions CFs**") are, and remain, fit and proper in accordance with Irish regulatory requirements.

In assessing whether a person is fit and proper to be a Key Function Holder, the Company considers the following regulatory prescribed criteria in relation to that person:

- personal characteristics (including being of good repute, honesty, integrity and financial soundness);
- (a) the level of competence, knowledge & experience;
- (b) qualifications and professional standards; and
- (c) the training undertaken or to be undertaken by that person.

In relation to (a) and (b), the Company looks for evidence that the person has:

- appropriate qualifications;
- experience and knowledge in insurance and financial markets;
- an understanding of the Company's business strategy, business model and system of governance;
- an understanding of financial and actuarial analysis (to the extent applicable);
- knowledge of the legal and regulatory framework and requirements applicable to the Company and its business; and
- the ability to adequately support the sound and prudent management of the Company.

The above criteria are assessed prior to the person's appointment as a PCF/CF through self-assessment questionnaires, interviews with the Human Resources team senior management and third-party background checks (covering employment references, criminal records checks, credit checks and academic/professional body checks), as appropriate to the function concerned.

Once appointed, the person is subject to periodic fitness and propriety checks by the Company. This fit and proper process and the appointment of PCF/CF is overseen by the Board.

In addition to the above, the Company has a robust recruitment process and performs appropriate employment checks on all other employees operating within the key functions of the Company's business. This is overseen by the Chief Executive Officer in conjunction with the Human Resources team.

B.3 Risk Management System

B.3.1 Risk Management Function and System

The Board has delegated oversight of the risk management system to the Risk Committee. The Chief Risk Officer is responsible for discharging, managing, and the day-to-day oversight of, the Company's risk management function and reporting to the Risk Committee in respect of this. The risk management function is responsible for the implementation of the Company's risk management system.


The Risk Committee has approved the implementation of a risk management system to identify, measure and track risk indicators for the Company. The risk management system includes a risk appetite statement, risk register, risk tolerances and a risk scorecard for monitoring performance against qualitative and quantitative tolerances.

An independent non-executive director chairs the Risk Committee, which meets regularly to review business performance metrics, business developments and other material changes which could impact the risk profile of the business.

The CRO presents quarterly risk updates to the Risk Committee, which includes:

- executive summary of the business issues reviewed by the management risk committee.
- risk scorecard summary.
- risk tolerances summary.
- solvency capital summary; and
- an overview of the risk management process.

The Company's risk management ("RM") process can be summarised using the following diagram:



B.3.2 Own Risk Solvency Assessment ("ORSA")

Process

The ORSA is a forward-looking risk assessment of the Company's material risks in the context of its business strategy and risk appetite, in order to determine current and the future solvency needs of the business. The Company's ORSA process is governed by its ORSA policy, which describes the purpose, process and governance over the ORSA.

The Board is responsible for the Company's ORSA and ensuring that it is performed in accordance with the ORSA policy and applicable law and regulation.

The ORSA process is coordinated by the Chief Risk Officer. The objective of the ORSA process is to assess its capital adequacy in light of its assessment of its risks and the potential impacts of its risk environment and enable it to make strategic decisions.

The risk management reporting to the Risk Committee supports the objectives of the ORSA by presenting regular updates on the Company's risk profile. The risk scorecard is used to track emerging risk issues that impact the Company's ability to manage its solvency capital.

The key risk assurance functions which provide updates to the Risk Committee as part of the ORSA process are:

- the CRO manages the ORSA process and its outputs, which identifies the key risks; and
- the actuarial function which runs tests on the Company's balance sheet for capital adequacy and produces the resultant output.

The Board reviews the report following completion of the ORSA process and considers the need for any management actions to be incorporated into the final ORSA report, such as:

- assessment of the appropriateness of the Solvency II Standard Formula for determining the Solvency Capital Requirements of the Company;
- review of the Company's solvency capital calculations and scenarios;
- decisions in relation to its capital;
- reassessment of the Company's risk profile and appetite;
- additional risk mitigation actions; and
- reassessment of the Company's investment strategy.

The results and conclusions contained in the final ORSA report and the Board's resultant actions and decisions, are communicated to all relevant staff, including outsourced control functions, once the report has been considered and approved by the Board.

Frequency

The ORSA process is repeated and an ORSA report prepared annually or earlier when certain material trigger events occur, as decided upon by the Company's Risk Committee in concert with the Board and in accordance with the ORSA policy.

Interaction of solvency and capital management with risk profile

The capital management process monitors the capital requirements for the Company on a quarterly basis. As part of this, the CRO prepares risk scorecard summaries, which include tolerances for monitoring the Own Funds available to meet the Company's Solvency Capital Requirement and Minimum Capital Requirement.

The solvency monitoring is reviewed under the capital management process so that any changes in business circumstances or its risk profile can be tracked for additional capital requirements.

The Company determined that the Solvency II Standard Formula would be used to calculate the required solvency capital and to assess the overall solvency needs. The Company administers a mono-line product with a short tail risk and the Solvency II Standard Formula is appropriate for the level of complexity in the Company's business. The AM Best capital model was also used to check capital requirements and the capital assessment under this model was slightly lower than the capital requirements under the Solvency II Standard Formula.

B.4 Internal Control System

B.4.1 Three Lines of defence

The Company operates a “three lines of defence” internal control system:

- **First line – Business Controls**

The Board owns and manages the risks of the Company and has responsibility for the Company's compliance with the requirements associated with the legal and regulatory environment in which it operates. The Board has implemented systems and controls, including appropriate internal policies and procedures, to comply with such requirements and to manage risks and monitor these alongside the development of its business strategy.

The Chief Executive Officer has been delegated responsibility by the Board for management of compliance with business controls and is responsible for reporting on such matters to the Board and its sub-committees.

- **Second line – Internal Control Functions**

The compliance and risk management functions form the second line of defence to ensure that the Company has an effective risk management control system. Further detail on the Company's compliance function is provided below.

- **Third line – Internal Audit Function**

The internal audit function forms the final layer of the internal control system and is an independent and objective function which is ultimately responsible for providing the Board with assurance that the Company has effective internal controls. Further detail on the Company's internal audit function is provided in Section B5 below.

B.4.2 Compliance Function

The Compliance Function is responsible for:

- **Compliance Risk Monitoring**

The Compliance Function identifies, assesses, monitors and reports to the Board (via the Audit Committee) on the Company's compliance risks (including the risk of it incurring legal and regulatory sanctions, significant financial loss, significant strategic or operational disruption, significant policyholder detriment or damage to reputation as a result of the Company's failure to comply with applicable laws and regulations). This includes reporting on any material non-compliance by the Company with such measures and/or any applicable law and regulation.

- **Supporting the implementation of legal & regulatory changes and internal controls**

The Compliance Function assists the business with the implementation of controls to address changes in the legal and regulatory environment and manage compliance risk. This includes advising the Board on the Company's compliance with the rules and other laws, regulations and administrative provisions adopted in accordance with the Solvency II Directive.

- **Regulatory reporting and correspondence**

The Compliance Function coordinates and oversees the preparation and filing of non-finance related regulatory reports and correspondence with the Company's regulators.

The Head of Compliance is responsible for discharging, managing and overseeing the Company's compliance function. He or his delegate reports to the Audit Committee on compliance matters on a quarterly basis – this includes details of any material compliance breaches and any corrective action undertaken in the previous reporting period.

The compliance function also provides updates on compliance activity at monthly Legal, Audit, Risk and Compliance management committee meetings, which are comprised of senior management and individuals from other key functions.

The Head of Compliance has a reporting line into the Chief Executive Officer in respect of day-to-day compliance matters and also an internal reporting line into a regional Director of Compliance, within the Aetna International business.

There is a compliance policy which is reviewed annually and approved by the Board. The Compliance Officer is responsible for this policy and ensuring that it is implemented. The Board ensures that the compliance function has the necessary access to all personnel (including third parties with whom the Company deals), systems and records in order that it can perform its role in full support and adherence of the compliance policy.

B.5 Internal Audit Function

The internal audit function of the Company is responsible for providing the Board with independent and objective assurance in respect of the Company's system of governance; in particular, it assists the Company in accomplishing its objectives by bringing a systematic and disciplined approach to evaluate and improve the effectiveness of the organisation's governance, risk management, internal control.

There is a dedicated internal audit team in the UK which has a primary focus on Aetna International's business and specifically covers the Company. This team forms part of the wider CVS Group internal audit function which is headed by the Head of Internal Audit for CVS Healthcare Group

The Company's Head of Internal Audit is primarily responsible for overseeing and discharging the Company's internal audit function with the support of the internal audit team.

The Company's Head of Internal Audit reports to the Company's Audit Committee on a quarterly basis. This reporting structure ensures that audit issues and action plans receive adequate consideration and effective action.

The Company's internal audit charter also provides a mechanism for the Chairman of the Audit Committee to engage directly with the head of the internal audit function, independent of the executive management.

The planning process includes management input, a review of emerging risks and professional auditor judgment. The internal audit charter for the Company also provides for the Audit Committee to request ad-hoc or specific internal audit reviews for the Company, if the Audit Committee deems this necessary. The Audit Committee approves the annual internal audit plan for the Company.

Results and conclusions of audit work are reviewed with operating and financial management directly responsible for the activity being evaluated and other management, as deemed appropriate.

The purpose of reviewing results is to reach an agreement as to the facts presented by the auditors and to obtain management action plans to address issues. Communications include the engagement's objectives and scope, as well as applicable conclusions, recommendations, and action plans.

Once an audit is completed and results are communicated, the internal audit function follow-up to ensure that management action plans ("MAPs") are effectively implemented. The status of all management action plans will be reported quarterly to the Company's senior management and Audit Committee, with specific details around any MAPs delayed past their due date.

B.6 Actuarial Function

The actuarial function is responsible for the following activities:

- co-ordination of the calculation of technical provisions. This consists of assessing the sufficiency of the provisions, assessing the uncertainty in the estimates and justifying the differences between successive periods;
- reviewing the appropriateness of the models and assumptions, considering the sufficiency and quality of data, and interpreting deviations of best estimates against experience. There is also a requirement to consider the verifiability of assumed management actions;
- providing opinions on underwriting policy and any reinsurance arrangements;
- contributing to the effective implementation of the risk management system of the Company. In particular:
 - in relation to the Solvency Capital Requirement ("SCR") and Minimum Capital Requirement ("MCR"), the Company's Chief Actuary reviews the output of the model used by the Company to calculate the SCR and MCR. Specifically, any perceived or possible inconsistencies or issues identified in the model results are raised; and
 - the Chief Actuary approves the preparation of the ORSA presented to the Risk Committee in conjunction with the risk management function.

The Head of Actuarial & Underwriting is responsible for discharging, managing and overseeing the actuarial function. In addition to ad-hoc updates to the Board and Risk Committee (as may be required from time to time), the Head of Actuarial is required to produce an annual report for the Board. This report covers all of the information necessary for the Board to form its own opinion on the adequacy of technical provisions and on the underwriting and reinsurance arrangements of the Company.

B.7 Outsourcing

The Company outsources and enters into outsourcing arrangements only where there is a sound commercial basis for doing so, and where the risk can be effectively managed. A due diligence process is undertaken prior to any final decision being made as to whether to outsource a material business activity. This addresses all material factors that would impact on the potential service provider's ability to perform the business activity.

The Company uses Group expertise to put in place some arrangements; refer to the table below. The Group completes the initial due diligence for these external service providers and ensures all required subsidiary undertakings within the Group are covered under the sub-contract with external providers.

The Company's management ensure that the contracts comply with the Board approved outsourcing policy. The Company's management are responsible for the oversight of all outsourcing arrangements.

The Company has established an Outsourcing Policy setting out the requirements for identifying, justifying and implementing material outsourcing arrangements. This Policy has been adopted by the Company and covers the following:

- definition of outsourcing;
- risk assessment;
- Board and management responsibility;
- internal control procedures;
- due diligence;
- business continuity management;
- contractual agreements;
- management and control of the outsourcing relationship; and
- final approval.

The Company's outsourcing arrangements are subject to an annual review and a report with any findings from that review are presented to the Board. The following table details the critical or important operational functions the Company has outsourced together with the jurisdiction in which the providers of such functions or activities are located:

Service Provider	Service Outsourced	Jurisdiction	AHICE Outsourcing Oversight
Aetna Global Benefits (UK) Limited	Sales Management Operations (routine back office policy administration) Complaints Administration Actuarial Analysis Finance Operations Internal Audit reviews Legal support Information Technology and Infrastructure	United Kingdom	Chief Executive Officer/ Chief Finance Officer
Aetna Life Insurance Company ("ALIC")	Investment Management Treasury Management Information Technology Outsourcing sub-contracts (see below)	United States of America	Chief Finance Officer
PwC	Tax compliance services	Ireland	Chief Finance Officer
HGS	Claims processing (back office)	India	Chief Executive Officer
Genpact	Call centre	Manila	Chief Executive Officer
Microsoft	Cloud services (Azure) for information systems, networking & disaster recovery.	UK	Chief Risk Officer

B.8 Any other information

The Company has assessed its system of governance and has concluded that it effectively provides for the sound and prudent management of the business and that it is proportionate to the nature, scale and complexity of the operations of the Company.

There were no material changes to the system of governance during 2022 (save as those noted elsewhere in this report).

C. RISK PROFILE

Risk management objectives and risk policies overview

The Company is exposed to a variety of risks when undertaking its activities. The Board has policies in place to identify and manage the key risks in accordance with its risk appetite. The key risks that the Company is exposed to are as follows:

- underwriting (insurance) risk;
- market risk;
- credit risk;
- liquidity risk;
- operational risk; and
- regulatory risk and capital management

The following sections outline the Company's views on each of these risks and the measures and controls in place to manage them.

C.1 Underwriting Risk

The Company stopped writing all business on 31st October 2022 and the Board confirmed the decision to enter into run-off on 21st November 2022. Prior to this, the migration of business as agreed in the APA commenced on a phased basis in July 2022, with all company risks expected to expire by 31st October 2023. AHICE also entered into a reinsurance agreement with ALIC, effective from 1 January 2023, to cover all claims paid after that date. The underwriting risk has therefore significantly diminished for the Company.

With the Company entering run-off and retaining some unexpired risks, the key elements of the Company's insurance risk management framework are reserving risk and reinsurance risk.

Reserving risk

To manage reserving risk and ultimate reserves risk, management employs a number of techniques to monitor premium and claims development patterns. An external independent actuary also performs an annual review of the claim's methodology.

The objective of the Company's reserving policy is to produce accurate and reliable estimates that are consistent over time. The reinsurance agreement with ALIC also reduces the reserving risk significantly.

Reinsurance strategy

The Company will enter into 100% quota share ("QS") reinsurance agreement with Aetna Life Insurance Company, a related party in the CVS Health Group. The purpose of the QS is to provide policyholders with an additional level of security during run-off. ALIC is contractually bound to provide funds to cover all of the claim's liabilities that fall due as the business runs off. The QS reinsurance is effective from the 1st January 2023 and provides cover for both future periods from in force contracts and well as historic claims periods. The reinsurance will continue for the duration of the run-off period on a funds withheld basis. AHICE will not transfer any cash to ALIC until the termination of the reinsurance and will aim to retain sufficient cash resources to meet the expected claims liabilities during run-off.

The Company previously had in place an excess of loss reinsurance arrangement with Aetna Life & Casualty (Bermuda) Limited, also a related party in the CVS Health Group, and this reinsurance arrangement was fully commuted on the 31st December 2022.

Material changes to the measures used to assess underwriting risk

There were no material changes to the measures used to assess underwriting risk in the period.

C.2 Market Risk

Market risk is the risk that changes in market prices, such as interest rate, foreign exchange rates and prices will affect the value of the Company's assets, the amount of its liabilities and/or the Company's income.

The Board approved investments parameters recognise the "prudent person principle" in relation to the management of assets held by the Company, including selection criteria to ensure the assets selected meet clearly identifiable, easily tradable, meet minimum credit rating criteria and that the market valuation can easily be verified by an independent party.

The components of the Company's market risk are shown below.

Market Risk Component	Description
Spread risk	The potential financial loss due to the increase in spread that an asset trades at relative to comparable government bonds.
Currency risk	The potential financial loss due from the change in currency exchange rates causing an adverse change in value of the liabilities compared to assets held.
Interest rate risk	The potential financial loss due to a reduction in value of the investment portfolio due to a change in interest rates.

Spread risk mitigation

There are investment parameters approved by the Board, which focus on high quality debt instruments. The investment assets include highly liquid, commercial paper (cash equivalents), due to the low yields possible in Euro bond market. The Board reviews performance against the investment parameters and their effectiveness on a quarterly basis and the investment parameters are reviewed and approved by the Board annually. The current investment parameters are an effective control against a market change in spread risk.

Currency risk mitigation

Management reviews the matching of assets and liabilities regularly and reports to the Board (who discusses the effectiveness of the mitigation) on a quarterly basis. There are no material market currency risks which require action.

Interest rate risk mitigation

Interest rate risk is the risk that the unfavourable movements in interest rates could adversely impact on the capital values of the Company's financial assets and liabilities.

The investment strategy approved by the Board is focused on high quality, short duration debt instruments.

The Company transacts business with insureds who are domiciled in countries within the EU. These insurance contracts are therefore principally denominated in euro and therefore the Company's functional currency is euro.

The Company investment parameters permit investments into corporate bonds and commercial paper. Since the funds are short term, they are not subject to large movements from changes in interest rates. The Company does not hold any external borrowings as part of its financial liabilities profile at the valuation date, further reducing potential exposure to any movement in market interest rates.

The Board reviews performance against the investment strategy and their effectiveness on a quarterly basis and the investment strategy is reviewed and approved by the Board annually. The quarterly monitoring of asset duration is effective for mitigating against changes in interest rates.

Any interest rate risk arising on the Company is considered to be minimal.

Material changes to the measures used to assess market risk

There are no material changes to the measures used to assess market risk as listed during 2022.

C.3 Credit Risk

The Company defines credit risk as the risk of financial loss to the Company should a counterparty fail to meet its contractual obligations.

The Company only holds investment and cash balances in accordance with the credit ratings specified in the Board approved investment parameters (which as noted earlier recognise the "prudent person principle") to mitigate the risk of financial loss from counterparty default. The Company has used credit quality steps based on ratings from its nominated External Credit Assessment Institutions ("ECAIs") when calculating its counterparty default risk.

The Company's investments and cash ratings are represented in the table below:

Asset Class	Credit Rating	ECAI	% Held	Solvency II Credit Quality Step
Cash	BBB	Moody	86%	1
Commercial Paper	A	S&P	14%	2

An update of the Company's investments and cash ratings are presented to the Board on a quarterly basis which monitors the effectiveness of, and compliance with, the investment parameters. The risk appetite for the range of credit ratings allowable for investments and the quarterly monitoring is effective in managing the default risk from counterparties.

Policyholder receivable balances are diversified, but unrated, and are continually monitored by the Company's credit control function for impairment, with policies suspended and or cancelled in the event a policyholder breaches premium payment terms.

C.4 Liquidity Risk

Liquidity risk is the risk that the Company does not have timely access to sufficient cash reserves in order to satisfy its obligations as they fall due.

The Company's principal obligations relate to the settlement of claims arising on its insurance contracts. The nature of the Company's insurance activities is such that the profile of claims incurred follows a high frequency, low severity profile.

Such a profile lends itself more readily to cash requirement forecasting than low frequency high severity insurance lines of business such as property catastrophe, thereby reducing inherent liquidity risk.

The Company's finance function forecasts cash requirements on a quarterly basis, managing its available cash resources accordingly. The forecasting process takes into account the nature and duration of technical provisions in accordance with the "prudent person principle" under Solvency II rules.

The level of cash retained versus cash released for investment is monitored and reported to the Board. The Board sets minimum cash balances to be maintained, depending on the volatility expected in the cash flow forecasts.

The table below provides details of the liquidity and duration of Company's financial assets as at 31 December 2022 and shows that there is cash and commercial paper of €21,470k to meet the technical provisions of €6,757k (2021: €5,177k):

Financial Investments	2022 €'000	2022 %	2021 €'000	2021 %
Cash on demand	18,422	86%	17,820	86%
Commercial paper (within 1 month)	3,048	14%	2,849	14%
Total	21,470	100%	20,669	100%

Premium collection is being monitored very closely during the run-off and there are sufficient liquid assets to cover liquidity requirements throughout 2022.

Change in measures used to assess liquidity requirements

The calculation of the technical provisions includes anticipated margin on the unwinding of future cash flows with full provision maintained for past due premiums.

C.5 Operational Risk

Operational risk is the risk of direct or indirect loss arising from a wide variety of causes associated with the Company's processes, personnel, technology and infrastructure, and from external factors other than credit, market and liquidity risks, such as those arising from legal and regulatory requirements and generally accepted standards of corporate behaviour.

Operational risks arise from all of the Company's operations, including activities outsourced to related parties within the CVS Group. The Company's objective is to manage operational risk so as to balance the avoidance of financial losses and damage to the Company's reputation with overall cost effectiveness and to avoid control procedures that restrict initiative and creativity.

The primary responsibility for the development and implementation of controls to address operational risk is assigned to senior management and is overseen by the Board. Compliance with the Company's standards is supported by a programme of periodic reviews undertaken by the internal audit function.

The results of internal audit reviews are discussed with management, with summaries submitted to the Audit Committee.

The Company also considers different stress scenarios, including failure of IT operating platforms, loss of key talent and the loss of Dublin office. The CVS Group maintains strict security protocols for all hardware and software used within the Group, whereby all Group sites are subject to Group protocols in relation to the installation of IT software and IT infrastructure. The Group IT security function operate scanning controls across all applications and software used by the Company. There are escalation procedures in place for any identified cyber threats and Group IT Security provide summary IT security reports on a quarterly basis to the Board. The Board has also approved risk tolerances for the level of notifiable security breaches and these are included in the quarterly risk scorecard presented to the Board.

There are documented controls included in the Company ORSA which mitigate against the loss of operations for these key risks. There are documented procedures for the key controls and monitoring processes.

Under the reverse stress tests documented in the ORSA, the most extreme and unlikely event to impact the operations of the Company would be if the CVS Group was unable to continue operations. A secondary event which could disrupt operations would be a major incident at the Dublin office. However, the disruption caused by any such event would be reduced by activating the business continuity plan, which is regularly tested and documented.

There were no material changes to the Company's outsourcing risk profile during the period.

C.6 Stress Testing and Sensitivities

The Company has performed stress and scenario testing of the material risks to which it is exposed. The Company has sufficient Own Funds to meet its SCR and MCR. There are no realistic stress scenarios that could bring the Company's Own Funds below its SCR or MCR and the Company is more than adequately capitalised to absorb losses.

The Company also completes reverse stress tests on an annual basis to examine the conditions that would render the Company's business model unviable.

The table below provides summary details of the stress and scenario testing completed for the Company's run-off:

Type of Test	Risks Covered	Timeline
Stress & Scenario Testing:		
Business Planning	Material risks over 1-year planning period	Annually
	Material risks over 3-year planning period	Annually
Risk specific	Liquidity risks	Monthly
	Market risks	Quarterly
Reverse Stress Testing:		
Business Planning	Solvency & Capital	Annually
	Liquidity	Annually
Strategic	Strategic & reputational	Annually

In order to monitor the severity and impact of material risks on the Company's run-off plans, the stress tests detailed in the table below were included as part of the Company's ORSA:

Test	0	1	2	3	4	5
EUR €m	FY 2022* Forecast	FY 2023* Forecast	FY 2024* Forecast	FY 2025* Forecast	FY 2026* Forecast	FY 2027* Forecast
Capital surplus over 150% solvency ratio after capital extraction	6.3	4.3	4.4	4.5	4.6	4.7
G&A cashflows subject to stress	-	3.0	0.6	0.1	0.2	0.4
% inflation stress in each year	-	20%	20%	20%	20%	20%
Cumulative inflation stress	-	0.6	0.9	1.0	1.1	1.7
Capital surplus after G&A inflation stress	6.3	3.7	3.5	3.5	3.5	3.0
Medical cost inflation stress						
Gross incurred claims subject to medical inflation	5.4	2.1	-	-	-	-
% inflation stress in each year	20%	20%	-	-	-	-
Cumulative inflation stress	1.1	2.0	2.0	2.0	2.0	2.0
Capital surplus after medical cost inflation stress (excluding RI)	5.2	2.0	2.4	2.5	2.6	2.7
Capital surplus after medical cost inflation stress (including RI)	5.2	4.0	4.4	4.5	4.6	4.7
Combined G&A and medical cost inflation stress						
Capital surplus after combined G&A and medical cost inflation stress (excluding RI)	5.2	1.4	1.5	1.5	1.6	1.0
Capital surplus after combined G&A and medical cost inflation stress (including RI)	5.2	3.3	3.5	3.5	3.6	3.0

The test results were performed for the Company's run-off plans approved by the Board on 21st November 2022. The data used for the base scenario testing, was based on forecast planning assumptions in line with the cessation of writing business on 31st October 2022.

In addition to the stress tests completed above, the Company also identified circumstances that could potentially render its business model unviable, including the effects of the failure of the parent company and the impact of significant operational failures or regulatory interventions on the business that could result in business failure. There were no results creating additional actions for the Company.

C.7 Regulatory risk and capital management

Regulatory risk is the risk that the Company breaches the requirements of local regulatory bodies, most notably the Central Bank of Ireland. The Company mitigates this risk through the effective operation of defined governance structures and effective capital management. The Company is required to hold sufficient capital to comply with the capital requirements under the Solvency II directive. The Company has complied with these capital requirements throughout the period. Management also carries out its own assessment of the level of capital resources it regards as appropriate in excess of these regulatory minima.

C.8 Other Material Risks

Climate Change

The risk management framework has been updated to ensure any risks resulting from climate change are tracked for their impact to the Company's business, including any potential impact for the Company's existing customer base.

Whilst there are no material risks emerging from climate change which impact the Company's business at this time, management continue to review the potential impact of climate change with other parts of the CVS/Aetna Group.

As opportunities arise to renew office occupancy, management will consider office requirements under flexible working arrangements and ESG factors for choice of office location.

There are no other material risks to report in respect of the Reporting Period.

C.9 Other material information

The information presented in Section C explains the Company's risk profile. There is no other additional information to disclose.

D. VALUATION FOR SOLVENCY PURPOSES

The following table analyses the Company's assets and liabilities on 31st December 2022, showing the movement between the FRS valuation and the Solvency II valuation.

Net Assets	Notes	FRS	Adjustments	Solvency II	Solvency II
		2022	2022	2022	2021
		€'000	€'000	€'000	€'000
Deferred acquisition costs	1	244	(244)	-	-
Deferred Tax	2	-	-	-	-
Financial Assets	3	3,048	-	3,048	2,849
Reinsurance Recoverables	4	304	(138)	166	396
Insurance Receivables	5	3,536	(1,840)	1,696	2,039
Trade Receivables	6	48	-	48	35
Cash & Cash Equivalents	3	18,422	-	18,422	17,820
Total Assets		25,603	(2,222)	23,380	23,139
Technical Provisions	7	6,599	159	6,757	5,142
Insurance Balances payable	8	1,373	(1,191)	182	392
Reinsurance payables		4	-	4	35
Trade Payables	10	2,063	(236)	1,826	444
Other Liabilities	11	975	-	975	93
Total Liabilities		11,013	(1,269)	9,744	6,106
Net Assets/Own Funds		14,590	(954)	13,636	17,033

D.1 Assets

Assets are valued at the amounts for which they could be exchanged between knowledgeable, willing parties in an arm's length transaction. The classes of assets stated in the economic balance sheet are valued individually. The Company closely monitors the valuation of assets and considers if there are any changes in circumstances which might require a change in the valuation applied.

The Company also applies the materiality principle, applying judgements to estimates and estimation methods where necessary. The principles that have been applied to the valuation of the financial assets is detailed further below:

Note 1: Deferred Acquisition Costs

Deferred acquisition costs of €244k are excluded from the valuation of assets for solvency purposes. Under Solvency II rules, the value of deferred acquisition costs was recognised at nil.

Note 2: Deferred Tax

Deferred tax is estimated using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes.

A deferred tax asset is not recognised in the 2022 Solvency II balance sheet as there is insufficient evidence at the reporting date in relation to the timing of the future economic benefits for the

utilisation of the cumulative tax losses. This position is not expected to change during run-off.

Once the Company commences writing business, the underwriting margins are expected to exceed the costs attributable to running the business in future periods and to generate future profits.

Note 3 Financial Investments + Cash & Cash Equivalents

Financial Investments	2022	2022	2021	2021
	€'000	%	€'000	%
Cash on demand	18,422	86%	17,820	86%
Commercial paper (within 1 month)	3,048	14%	2,8491	18%
Total	21,470	100%	20,669	100%

The financial assets include investments in corporate bonds and commercial paper in accordance with the Board approved investment parameters. The assets are included at fair value using a mark-to-market approach, based on readily available prices that are sourced independently. The investments are valued under the Level 1 (14% of total value of financial investments) and the Level 2 tier of fair value hierarchy, where there are quoted prices in active markets for the same assets. Accrued income included in trade receivables under FRS rules, is added to the market value of the investment bonds under Solvency II valuation rules. There has been no adjustment to the valuation of the financial investments in the Company's financial statements for the Reporting Period and the valuation is based on quoted market prices at the valuation date.

The Board reviews the management of the investment portfolio. There are investment parameters approved by the Board for the investment manager, which include parameters for monitoring the credit ratings applied to assets in the investment portfolio. Two or more credit ratings will be checked, if available and the lower of the two applied or the second from lowest if more than two credit ratings available. The valuation of the assets includes details of credit rating selected by the investment manager for each asset held.

Cash held on deposit is valued at fair value, representing the valuation of the cash that could be exchanged between two knowledgeable parties in an arm's length transaction. As these are on-demand, the value of the deposit has not been discounted. These cash deposits are reclassified as financial assets in the Solvency II balance sheet.

Note 4: Reinsurance recoverable

The excess of loss reinsurance program that was in place for the prior period was fully commuted on 31st December 2022 and there are no future cashflows in or out under this program.

For the QS reinsurance arrangement that is effective from the 1st January 2023 with ALIC, the actuarial reserving director has reviewed the events that create a recoverable cash flow under the QS reinsurance and the amounts included in the valuation are consistent with the terms of the reinsurance agreement.

The QS reinsurance agreement will operate on a funds withheld basis, where the Company will retain sufficient funds to meet all its future expected claims. The amount included in the balance sheet represents a current estimate for the net cash reinsurance cash settlement in the future. This includes the assumed transfer of all existing policy liabilities and a recovery of the Company's claims handling costs for all future claims. The net settlement position at the end of the run-off period is assumed to be a cash outflow.

Note 5: Insurance Receivables

Insurance receivables comprise amounts past due at the valuation date. The reclassification adjustment below represents the movement of premiums not due at the valuation date out of non-technical assets and into the calculation of the technical provisions under Solvency II valuation rules. There are controls and procedures in place to check and ensure the accuracy of invoicing and the monitoring of premiums collected. Summary reports and analysis on the recoverability of debts is provided to senior management and the Board. The valuation of the asset takes into account the effectiveness of the controls and includes an allowance for unrecoverable debts. The valuation included in the Solvency II balance sheet represents all insurance balances past due, which are also expected to be paid in less than 12 months from the valuation date.

	FRS €'000	Valuation & Reclassification Adjustments	Solvency II Valuation Adjustments	Solvency II €'000	Solvency II €'000
	2022	2022	2022	2022	2021
Insurance Receivables	3,536	(1,840)	-	1,696	2,039

Note 6: Other Trade receivables

The receivables (trade, not insurance balances) relate to receivables from related party entities within the Group, which are due within 1 year and carrying value are taken to approximate fair values under Solvency II valuation rules. The value stated represents the amount that could be exchanged between two knowledgeable and willing parties in an arm's length transaction.

There was a small reduction in the outstanding balance during the year as the related party settled most of the outstanding balance. The 2022 valuation does not include prepayments (2021: €20k).

	FRS €'000	Valuation & Reclassification Adjustments	Solvency II Valuation Adjustments	Solvency II €'000	Solvency II €'000
	2022	2022	2022	2022	2021
Trade Receivables	48	-	-	48	35

D.2 Technical Provisions (Note 7)

The technical provisions are calculated for the Company's single line of business, Medical Expenses Insurance. The technical provisions comprise the Best Estimate Liabilities ("BEL") and the risk margin, under Solvency II rules. At 31st December 2022, the technical provisions were:

Technical Provisions	2022	2021
	€'000	€'000
Best Estimate Liabilities (BEL)	6,587	4,816
Risk Margin	170	326
Total	6,757	5,142

The technical provisions increased on prior year, primarily due to the additional allowance €2,449k (2021: nil) for run-off expenses. There are no other material changes to inputs and assumptions used for the valuation of the technical provisions.

BEL

The BEL is calculated as the sum of a Gross Premium Reserve and Gross Claims Reserve.

Gross Claims Reserve

The best estimate of provisions for claims outstanding (referred to as the Gross Claims Reserve) is the expected present value of all future claim and expense cash flows related to claim events that occurred prior to the valuation date. Any explicit prudence included in the FRS Outstanding Claims reserve is removed to calculate the best estimate Gross Claims Reserve. Claims cashflows are then projected based on historical payment patterns of the business.

An allowance is included for the best estimate value of expenses (including direct and indirect costs) relating to the settling of these claims.

An adjustment is also made to include other accounting liabilities representing future claims cash flows, such as claims payable that are not already included in the FRS Outstanding Claims reserve and ENIDs.

Gross Premium Reserve

The Gross Premium Reserve is the expected present value in respect of future claim, expense and premium cash flows relating to claims events occurring after the valuation date and before the end of the insurance coverage period for the relevant policies. This includes a transfer from insurance receivables for future premium cashflows due under policy contracts issued at the valuation date.

The claims cash flows for this reserve are calculated by projecting the future premiums to be earned on business that is legally bound at the valuation date (including business not yet incepted at the valuation date) to the end of the coverage period of the relevant policies.

Future expected incurred claims are projected by applying an appropriate loss ratio to the future earned premium; the corresponding claims cash flows are then projected based on historical payment patterns.

An allowance is included for the best estimate value of expense cash flows (including direct and indirect costs) relating to the settling of these claims and future administration of these policies. The Gross Premium Reserve includes allowance for the value of premiums not yet due and other relevant insurance receivables or payables.

The BEL claims cash flows include allowance for ENIDs so that the BEL reflects an expected probability-weighted average of future cash flows.

The cashflows for the Gross Claims Reserve and Gross Premium Reserve are then discounted at yields provided by EIOPA, depending on the projected timing and currency of the cashflows.

Risk Margin

The risk margin is calculated using the following assumptions:

- the business, including reinsurance, is transferred to a reference undertaking with no other insurance obligations or own funds before the transfer, and which does not write any further business (including renewals of existing business);
- the reference undertaking is capitalized as described under Solvency II rules; and
- the assets are selected to minimize market risk.

The SCR under the above assumptions is projected for future years using key risk drivers. The risk margin is calculated by multiplying the projected SCRs by a 6% Cost of Capital and discounting to the valuation date.

FRS value of technical reserves vs Solvency II Technical Provisions

The quantification of the difference between the FRS value of technical reserves and the Solvency II Technical Provisions for the Company is shown below:

Technical Provisions	2022	2021
	€'000	€'000
FRS Outstanding Claims Reserve (OCR)	3,095	2,566
FRS Unearned Premium Reserve (UPR)	3,504	6,542
FRS Technical reserve	6,599	9,108
<i>Remove:</i>		
Prudence in FRS Outstanding Claims Reserve	(216)	(177)
Unearned Premium Reserve	(3,504)	(6,542)
Premiums not yet due and other receivables/ payables	(649)	(2,212)
<i>Add:</i>		
Project Gross Premium Reserve claims Business Bound Not Incepted)	2,050	3,869
Additional allowance for Events Not In Data	51	305
Best estimate expense allowance for Net Bound But Not Incepted (BBNI) cashflows	2,256	2,161
Discounting of claims and expense cashflows	-	(1,696)
	-	-
Total FRS to Solvency II Best Estimate	(12)	(4,292)
Best Estimate Liability	6,587	4,816
Add Risk Margin	170	326
Technical Provisions	6,757	5,142

Technical Provisions - Uncertainty

The main sources of uncertainty in the technical provisions relate to cases where actual claims or expense experience may emerge to be worse than expected. The following are key areas where actual experience may differ from that assumed in the technical provision calculation:

- Actual claims experience for past dates of treatment could be higher than that estimated in the claims reserve.
- Claims experience on incepted and bound but not incepted contracts for future dates of treatment could be higher than that estimated in the premium reserve.
- Actual expense costs relating to claims yet to be paid could be higher than expected.

Note that a number of factors may affect the actual emerging experience in the above areas, such as individual large claims, particular population-based trends in a region or operational aspects such as delays in claims submissions from providers.

Given the small nature of the technical provisions, there are no scenarios that would materially impact the Company's solvency ratio.

D.3 Other Liabilities

Note 8: Insurance Balances payable

The insurance balances payable comprises amounts arising on direct insurance operations, which are not included in the technical provisions. Claims liabilities included under insurance balances payable in the FRS balance sheet are included in the calculation of the Technical Provisions under Solvency II valuation rules.

These balances include allowances for broker commissions and premium taxes payable.

These liabilities are measured as amounts past due, which represent the amounts expected to be paid, and are measured based on a valuation amount for which they could be settled between knowledgeable willing parties in an arm's length transaction.

Note 9: Trade and Other payables

Trade payables include amounts due to suppliers, public entities, etc, and which are not insurance related. Trade payables solely comprise amounts which fall due within 12 months and are considered to be held at fair value, representing the value at which the balances could be exchanged between two knowledgeable and willing parties in an arm's length transaction.

Note 10: Other liabilities

Other liabilities include amounts payable to related parties within the CVS Group. These liabilities are measured as past due at the valuation date and therefore represent the amount expected to be paid.

There were no changes to the base assumptions used in the calculation of liabilities for the Reporting Period.

D.4 Alternative Valuation Methods

There are no alternative valuation methods applied to the valuation of Company's assets.

D.5 Other Material Information

The information presented in Section D provides the valuation for Solvency Purposes of the Company during the period.

E. CAPITAL MANAGEMENT

E.1 Own Funds

Composition and quality of own funds

Under Solvency II regulation, capital is referred to as Own Funds and the regulation distinguishes between Basic Own Funds (BOF) and Ancillary Own Funds (AOF). There are tiers of Own Funds and restrictions applied to the extent to which the various components of Own Funds can be used to meet the capital requirements.

Equity in Financial Statements at 31st December 2020	Tier 1	Tier 2	Tier 3	Total	
				2022	2021
				€'000	€'000
Ordinary Share Capital	635			635	635
Capital contribution	23,345			23,345	23,345
Reconciliation Reserve	(10,344)			(10,344)	(6,947)
Basic Own Funds	13,636			13,636	17,033
Deferred Tax Asset	0			0	0
Eligible Own Funds available to meet SCR	13,636	0	0	13,636	17,033
Ratio of Eligible Own Funds to meet SCR	419%			419%	278%

The Company's ordinary share capital is classified as Tier 1 capital since the Company's Articles of Association do not prohibit the cancellation of dividends after they have been declared.

The Company has no restricted Tier 1 capital. There is just once class of ordinary share issued by the Company. All the issued shares are fully paid up. There are no other classes of shares issued, nor any subordinated loans issued by the Company.

Approach to Capital Management

Capital management focuses on ensuring that there is sufficient capital retained to meet the regulatory requirements (MCR and SCR). The finance function provides the Board and its Audit Committee with information on the Company's capital position and monitors the surplus in line with internal, regulatory and rating agency capital requirements. The finance, risk management and actuarial functions collaborate to provide the Board with internal and regulatory stress testing.

The Company Capital Plan aims to:

- document the regulatory and minimum capital levels under baseline and stress scenarios; and
- describe the capital implications and actions required in the event that a stress scenario occurs.

The Capital Plan is an analysis of the Company's capital sources and uses a three-year time frame that takes into consideration:

- macroeconomic and financial market scenarios;
- business and run-off plan;
- applicable regulations; and
- capital resources calculated under future scenarios using the Solvency II standard formula.

The Company has an active capital management process to ensure it meets regulatory capital requirements and rating agency expectations.

Details of the capital movements during the period are shown in the table below:

Capital issued	Opening 2022 €'000	New Issue €'000	Exchange Movement €'000	Closing 2022 €'000	Closing 2021 €'000
Ordinary Share Capital	635	0	0	635	635
Capital contribution	23,345	0	0	23,345	23,345
Total	23,980	0	0	23,980	23,980

The total eligible amount of own funds to cover the Solvency Capital Requirement ("SCR") is €13,636k and the total amount of unrestricted Tier 1 own funds to cover the Minimum Capital Requirement ("MCR") is €13,636k. The following table reconciles to the bridge between FRS and Solvency II as shown in section D of this document. The main driver for the change in the reconciliation reserve, is the change in the valuation of technical provisions. There are no material changes to the inputs or assumptions used for the valuation of the technical provisions.

Reconciliation Reserve	2022	2021
	€'000	€'000
Excess of Assets over Liabilities in Solvency II Balance Sheet	13,636	17,033
<hr/>		
Less:		
Ordinary Share Capital	635	635
Capital Contribution	23,345	23,345
<hr/>		
Reconciliation Reserve	(10,344)	(6,947)
<hr/>		

E.2 SCR and MCR

The amount of the Company's SCR and MCR at the end of the Reporting Period are €3,255k and €2,500k respectively.

SCR

The table below shows the components of the SCR (using the Standard Formula) at 31st December 2022.

SCR Calculation	2022	2021
	€'000	€'000
Market Risk	1,143	2,634
Default Risk	1,714	1,806
Health Risk	533	2,896
Diversification	(886)	(2,102)
Basic Solvency Capital Requirement	2,504	5,234
Operational Risk	751	882
SCR	3,255	6,116
Minimum Solvency Capital Requirement	2,500	2,500
Own Funds available to meet SCR/MCR:	13,636	17,033

MCR

The MCR was calculated using the following inputs:

- net of reinsurance BEL €6,422k.
- net of reinsurance written premiums in the 12 months to 31 December 2022 of €14,205k; and
- SCR of €3,255k

These inputs were used in the calculation according to Articles 248-253 of the Solvency II Directive.

The SCR is calculated using the Standard Formula with no undertaking specific parameters applied.

E.3 Material Changes in the SCR and MCR over the Reporting Period

There has been no material change in the methodology used to calculate the Company's MCR and SCR during the reporting period.

E.4 Use of duration-based equity sub-module in the calculation of the SCR

The Company did not make use of the duration-based equity risk sub-module in the reporting during the Reporting Period.

E.5 Differences between the Standard Formula and Internal Model used

The Company uses the Standard Formula to calculate the SCR and therefore no difference exists.

E.6 Non-Compliance

During the Reporting Period, there were no instances of non-compliance with the Solvency II capital requirements.

QRT Templates for the SFCR Public Disclosure

Appendix 1 Balance Sheet

S.02.01.02

Balance sheet

000s

		Solvency II value
		C0010
Assets		
Goodwill	R0010	
Deferred acquisition costs	R0020	
Intangible assets	R0030	
Deferred tax assets	R0040	
Pension benefit surplus	R0050	
Property, plant & equipment held for own use	R0060	
Investments (other than assets held for index-linked and unit-linked contracts)	R0070	3,048
Property (other than for own use)	R0080	
Holdings in related undertakings, including participations	R0090	
Equities	R0100	
Equities - listed	R0110	
Equities - unlisted	R0120	
Bonds	R0130	3,048
Government Bonds	R0140	
Corporate Bonds	R0150	3,048
Structured notes	R0160	
Collateralised securities	R0170	
Collective Investments Undertakings	R0180	-
Derivatives	R0190	
Deposits other than cash equivalents	R0200	
Other investments	R0210	
Assets held for index-linked and unit-linked contracts	R0220	
Loans and mortgages	R0230	
Loans on policies	R0240	
Loans and mortgages to individuals	R0250	
Other loans and mortgages	R0260	
Reinsurance recoverables from:	R0270	166
Non-life and health similar to non-life	R0280	166
Non-life excluding health	R0290	
Health similar to non-life	R0300	166
Life and health similar to life, excluding health and index-linked and unit-linked	R0310	
Health similar to life	R0320	
Life excluding health and index-linked and unit-linked	R0330	
Life index-linked and unit-linked	R0340	
Deposits to cedants	R0350	
Insurance and intermediaries receivables	R0360	1,696
Reinsurance receivables	R0370	
Receivables (trade, not insurance)	R0380	48
Own shares (held directly)	R0390	
Amounts due in respect of own fund items or initial fund called up but not yet paid in	R0400	
Cash and cash equivalents	R0410	18,422
Any other assets, not elsewhere shown	R0420	
Total assets	R0500	23,380

S.02.01.02

Balance sheet

000s

		Solvency II value
		C0010
Liabilities		
Technical provisions – non-life	R0510	6,757
Technical provisions – non-life (excluding health)	R0520	
Technical provisions calculated as a whole	R0530	
Best Estimate	R0540	
Risk margin	R0550	
Technical provisions - health (similar to non-life)	R0560	6,757
Technical provisions calculated as a whole	R0570	
Best Estimate	R0580	6,587
Risk margin	R0590	170
Technical provisions - life (excluding index-linked and unit-linked)	R0600	
Technical provisions - health (similar to life)	R0610	
Technical provisions calculated as a whole	R0620	
Best Estimate	R0630	
Risk margin	R0640	
Technical provisions – life (excluding health and index-linked and unit-linked)	R0650	
Technical provisions calculated as a whole	R0660	
Best Estimate	R0670	
Risk margin	R0680	
Technical provisions – index-linked and unit-linked	R0690	
Technical provisions calculated as a whole	R0700	
Best Estimate	R0710	
Risk margin	R0720	
Other technical provisions	R0730	
Contingent liabilities	R0740	
Provisions other than technical provisions	R0750	
Pension benefit obligations	R0760	
Deposits from reinsurers	R0770	
Deferred tax liabilities	R0780	
Derivatives	R0790	
Debts owed to credit institutions	R0800	
Financial liabilities other than debts owed to credit institutions	R0810	
Insurance & intermediaries payables	R0820	182
Reinsurance payables	R0830	4
Payables (trade, not insurance)	R0840	1,826
Subordinated liabilities	R0850	
Subordinated liabilities not in Basic Own Funds	R0860	
Subordinated liabilities in Basic Own Funds	R0870	
Any other liabilities, not elsewhere shown	R0880	975
Total liabilities	R0900	9,744
Excess of assets over liabilities	R1000	13,636

Appendix 2 Premiums Claims Expenses

S.05.01.01

Premiums, claims and expenses by line of business

000s

Non-Life (direct business/accepted proportional reinsurance and accepted non-proportional reinsurance)

	Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance)																Line of Business for: accepted non-proportional				Total
	Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Health	Casualty	Marine, aviation, transport	Property					
	C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0200				
Premiums written																					
Gross - Direct Business	R0110	19,534																			
Gross - Proportional reinsurance accepted	R0120																				
Gross - Non-proportional reinsurance accepted	R0130																				
Reinsurers' share	R0140	5,330															5,330				
Net	R0200	14,204															14,204				
Premiums earned																					
Gross - Direct Business	R0210	22,761																			
Gross - Proportional reinsurance accepted	R0220																				
Gross - Non-proportional reinsurance accepted	R0230																				
Reinsurers' share	R0240	5,449															5,449				
Net	R0300	17,312															17,312				
Claims incurred																					
Gross - Direct Business	R0310	12,056																			
Gross - Proportional reinsurance accepted	R0320																				
Gross - Non-proportional reinsurance accepted	R0330																				
Reinsurers' share	R0340	875															875				
Net	R0400	11,181															11,181				
Changes in other technical provisions																					
Gross - Direct Business	R0410	-255																			
Gross - Proportional reinsurance accepted	R0420																				
Gross - Non-proportional reinsurance accepted	R0430																				
Reinsurers' share	R0440																				
Net	R0500	-255															-255				
Expenses incurred	R0550	7,664															7,664				
Administrative expenses																					
Gross - Direct Business	R0610	1,540																			
Gross - Proportional reinsurance accepted	R0620																				
Gross - Non-proportional reinsurance accepted	R0630																				
Reinsurers' share	R0640																				
Net	R0700	1,540															1,540				
Investment management expenses																					
Gross - Direct Business	R0710																				
Gross - Proportional reinsurance accepted	R0720																				
Gross - Non-proportional reinsurance accepted	R0730																				
Reinsurers' share	R0740																				
Net	R0800																				
Claims management expenses																					
Gross - Direct Business	R0810																				
Gross - Proportional reinsurance accepted	R0820																				
Gross - Non-proportional reinsurance accepted	R0830																				
Reinsurers' share	R0840																				
Net	R0900																				
Acquisition expenses																					
Gross - Direct Business	R0910	885																			
Gross - Proportional reinsurance accepted	R0920																				
Gross - Non-proportional reinsurance accepted	R0930																				
Reinsurers' share	R0940																				
Net	R1000	885															885				
Overhead expenses																					
Gross - Direct Business	R1010	5,239																			
Gross - Proportional reinsurance accepted	R1020																				
Gross - Non-proportional reinsurance accepted	R1030																				
Reinsurers' share	R1040																				
Net	R1100	5,239															5,239				
Other expenses	R1200																				
Total expenses	R1300																7,664				

Appendix 3 Premiums Claims Expenses by Country

S.05.02.01

Premiums, claims and expenses by country
000s

Home Country - non-life obligations

		Home country
		C0080
Premiums written		
Gross - Direct Business	R0110	81
Gross - Proportional reinsurance accepted	R0120	
Gross - Non-proportional reinsurance	R0130	
Reinsurers' share	R0140	
Net	R0200	81
Premiums earned		
Gross - Direct Business	R0210	101
Gross - Proportional reinsurance accepted	R0220	
accepted	R0230	
Reinsurers' share	R0240	2
Net	R0300	99
Claims incurred		
Gross - Direct Business	R0310	70
Gross - Proportional reinsurance accepted	R0320	
Gross - Non-proportional reinsurance	R0330	
Reinsurers' share	R0340	
Net	R0400	70
Changes in other technical provisions		
Gross - Direct Business	R0410	-5
Gross - Proportional reinsurance accepted	R0420	
accepted	R0430	
Reinsurers' share	R0440	
Net	R0500	-5
Expenses incurred	R0550	39
Other expenses	R1200	
Total expenses	R1300	

Top 5 countries (by amount of gross premiums written) - non-life obligations

	Netherlands	Cyprus	Greece	Germany	Hungary
	C0090	C0090	C0090	C0090	C0090
	4169	1235	1230	895	600
	4,169	1,235	1,230	895	600
	3779	1409	1423	980	610
	67	25	25	18	11
	3,712	1,384	1,398	962	599
	3374	929	647	349	252
	3,374	929	647	349	252
	-154	-131	-140	-95	-47
	-154	-131	-140	-95	-47
	3291	625	449	324	402

Total Top 5 and home country - non-life

Total Top 5 and home country
C0140
8,210
8,210
8,302
148
8,154
5,621
0
5,621
-572
-572
5,130
5,130

Appendix 4 Non Technical Provisions

5.17.01.02

000s

Non-Life Technical Provisions

		Direct business and accepted proportional reinsurance											Accepted non-proportional reinsurance				Total Non-Life obligation	
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Non-proportional health reinsurance	Non-proportional casualty reinsurance	Non-proportional marine, aviation and transport		Non-proportional property reinsurance
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160		C0170
Technical provisions calculated as a whole	R0010																	-
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default associated to TP calculated as a whole	R0050																	-
Technical provisions calculated as a sum of BE and RM																		
Best estimate																		
<i>Premium provisions</i>																		
Gross	R0060	2,609																2,609
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0140	(119)																(119)
Net Best Estimate of Premium Provisions	R0150	2,728																2,728
<i>Claims provisions</i>																		
Gross	R0160	3,978																3,978
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected losses due to counterparty default	R0240	285																285
Net Best Estimate of Claims Provisions	R0250	3,693																3,693
Total Best estimate - gross	R0260	6,587																6,587
Total Best estimate - net	R0270	6,422																6,422
Risk margin	R0280	170																170
Amount of the transitional on Technical Provisions																		
Technical Provisions calculated as a whole	R0290	-																-
Best estimate	R0300	-																-
Risk margin	R0310	-																-
Technical provisions - total																		
Technical provisions - total	R0320	6,757																6,757
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected losses due to counterparty default - total	R0330	166																166
Technical provisions minus recoverables from reinsurance/SPV and Finite Re - total	R0340	6,591																6,591

Appendix 5 Non Life Insurance Claims

S.19.01.21

Non-life insurance claims

Gross Claims Paid (non-cumulative) - Development year. Total Non-Life Business

000s

		Development Year										
		0	1	2	3	4	5	6	7	8	9	10 & +
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110
Prior	R0100											
N-9	R0160											
N-8	R0170	14,122	488	60	39	8	-	-	-			
N-7	R0180	10,570	326	29	25	7	-	-				
N-6	R0190	349	2	3	-	1	-	-				
N-5	R0200	-	-	-	-	-	-					
N-4	R0210	-	-	-	-							
N-3	R0220	-	-	-	-							
N-2	R0230	20.0	60.0	6.0								
N-1	R0240	5,870	2,666									
N	R0250	8,830										

15
16
17
18
19
20
21

Gross Claims Paid (non-cumulative) - Current year,

		In Current year	Sum of years (cumulative)
		C0170	C0180
Prior	R0100		
N-9	R0160		
N-8	R0170	-	14,717
N-7	R0180	-	10,958
N-6	R0190	-	355
N-5	R0200	-	-
N-4	R0210	-	-
N-3	R0220	-	-
N-2	R0230	6	86
N-1	R0240	2,666	8,536
N	R0250	8,830	8,830
Total	R0260	11,502	43,483

Gross undiscounted Best Estimate Claims Provisions - Development year. Total Non-Life Business

		Development Year										
		0	1	2	3	4	5	6	7	8	9	10 & +
		C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300
Prior	R0100											
N-9	R0160											
N-8	R0170											
N-7	R0180											
N-6	R0190		0	0	29	8	0					
N-5	R0200	0	0	0	0	0	-					
N-4	R0210	0	0	0	0	-						
N-3	R0220	432	0	6	-							
N-2	R0230	137	61	-								
N-1	R0240	3185	104									
N	R0250	3,940										

		Year end (discounted data)
		C0360
Prior	R0100	-
N-9	R0160	-
N-8	R0170	-
N-7	R0180	-
N-6	R0190	-
N-5	R0200	-
N-4	R0210	-
N-3	R0220	-
N-2	R0230	-
N-1	R0240	99
N	R0250	3,879
Total	R0260	3,978

Appendix 6 Own Funds

S.23.01.01

Own funds

000s

		Total	Tier 1 - unrestricted	Tier 1 - restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35						
Ordinary share capital (gross of own shares)	R0010	635	635			
Share premium account related to ordinary share capital	R0030	-	-			
Initial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual-type undertakings	R0040					
Subordinated mutual member accounts	R0050					
Surplus funds	R0070					
Preference shares	R0090					
Share premium account related to preference shares	R0110					
Reconciliation reserve	R0130	(10,344)	(10,344)			
Subordinated liabilities	R0140					
An amount equal to the value of net deferred tax assets	R0160					
Other own fund items approved by the supervisory authority as basic own funds not specified above	R0180	23,345	23,345			
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds						
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds	R0220					
Deductions						
Deductions for participations in financial and credit institutions	R0230					
Total basic own funds after deductions	R0290	13,636	13,636	-	-	-
Ancillary own funds						
Unpaid and uncalled ordinary share capital callable on demand	R0300					
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and mutual - type undertakings, callable on demand	R0310					
Unpaid and uncalled preference shares callable on demand	R0320					
A legally binding commitment to subscribe and pay for subordinated liabilities on demand	R0330					
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340					
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	R0350					
Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0360					
Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0370					
Other ancillary own funds	R0390					
Total ancillary own funds	R0400					
Available and eligible own funds						
Total available own funds to meet the SCR	R0500	13,636	13,636			
Total available own funds to meet the MCR	R0510	13,636	13,636			
Total eligible own funds to meet the SCR	R0540	13,636	13,636			
Total eligible own funds to meet the MCR	R0550	13,636	13,636			
SCR	R0580	3,255				
MCR	R0600	2,500				
Ratio of Eligible own funds to SCR	R0620	419%				
Ratio of Eligible own funds to MCR	R0640	545%				

S.23.01.01.02

Reconciliation reserve

000s

		C0060
Reconciliation reserve		
Excess of assets over liabilities	R0700	13,636
Own shares (held directly and indirectly)	R0710	
Foreseeable dividends, distributions and charges	R0720	
Other basic own fund items	R0730	23,980
Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	R0740	
Reconciliation reserve	R0760	(10,344)
Expected profits		
Expected profits included in future premiums (EPIFP) - Life business	R0770	
Expected profits included in future premiums (EPIFP) - Non-life business	R0780	-
Total Expected profits included in future premiums (EPIFP)	R0790	-

Appendix 7 Solvency capital requirement

S.25.01.21

Solvency Capital Requirement - for undertakings on Standard Formula

Basic Solvency Capital Requirement

000s

		Gross solvency capital requirement	Simplifications
		C0110	C0120
Market risk	R0010	1,143	
Counterparty default risk	R0020	1,714	
Life underwriting risk	R0030	-	
Health underwriting risk	R0040	534	
Non-life underwriting risk	R0050	-	
Diversification	R0060	(886)	
Intangible asset risk	R0070	-	
Basic Solvency Capital Requirement	R0100	2,505	

Basic Solvency Capital Requirement (USP)

000s

		USP
		C0090
Life underwriting risk	R0030	
Health underwriting risk	R0040	
Non-life underwriting risk	R0050	

S.25.01.21.02

Calculation of Solvency Capital Requirement

000s

		Value
		C0100
Operational risk	R0130	751
Loss-absorbing capacity of technical provisions	R0140	-
Loss-absorbing capacity of deferred taxes	R0150	-
Capital requirement for business operated in accordance with Art. 4 of Directive 2003,	R0160	-
Solvency Capital Requirement excluding capital add-on	R0200	3,255
Capital add-on already set	R0210	-
Solvency capital requirement	R0220	3,255
Other information on SCR		
Capital requirement for duration-based equity risk sub-module	R0400	-
Total amount of Notional Solvency Capital Requirements for remaining part	R0410	-
Total amount of Notional Solvency Capital Requirements for ring fenced funds	R0420	-
Total amount of Notional Solvency Capital Requirements for matching adjustment p	R0430	-
Diversification effects due to RFF nSCR aggregation for article 304	R0440	-

Appendix 8 Minimum Capital requirement

5.28.01.01

Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity
000s

		MCR components	
		C0010	
MCR _{ML} Result	R0010		969

				Background information	
		Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance) written premiums in the last 12 months		
		C0020	C0030		
Medical expense insurance and proportional reinsurance	R0020	6,422			14,205
Income protection insurance and proportional reinsurance	R0030				
Workers' compensation insurance and proportional reinsurance	R0040				
Motor vehicle liability insurance and proportional reinsurance	R0050				
Other motor insurance and proportional reinsurance	R0060				
Marine, aviation and transport insurance and proportional reinsurance	R0070				
Fire and other damage to property insurance and proportional reinsurance	R0080				
General liability insurance and proportional reinsurance	R0090				
Credit and suretyship insurance and proportional reinsurance	R0100				
Legal expenses insurance and proportional reinsurance	R0110				
Assistance and proportional reinsurance	R0120				
Miscellaneous financial loss insurance and proportional reinsurance	R0130				
Non-proportional health reinsurance	R0140				
Non-proportional casualty reinsurance	R0150				
Non-proportional marine, aviation and transport reinsurance	R0160				
Non-proportional property reinsurance	R0170				

Linear formula component for life insurance and reinsurance obligations

		C0040	
Linear formula component for life insurance and reinsurance obligations	R0200		-

Total capital at risk for all life (re)insurance obligations

		Non-life activities	
		Net (of reinsurance/SPV) best estimate and TP calculated as a whole	Net (of reinsurance/SPV) total capital at risk
		C0050	C0060
Obligations with profit participation - guaranteed benefits	R0210		
Obligations with profit participation - future discretionary benefits	R0220		
Index-linked and unit-linked insurance obligations	R0230		
Other life (re)insurance and health (re)insurance obligations	R0240		
Total capital at risk for all life (re)insurance obligations	R0250		

Overall MCR calculation

		C0070	
Linear MCR	R0300		969
SCR	R0310		3,255
MCR cap	R0320		1,465
MCR floor	R0330		814
Combined MCR	R0340		969
Absolute floor of the MCR	R0350		2,500
Minimum Capital Requirement	R0400		2,500

This document is available on the Aetna International website